Shiraishi N, Rehm S, Waalkes M P
Inorganic Carcinogenesis Section, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
J Toxicol Environ Health. 1994 Jun;42(2):193-208. doi: 10.1080/15287399409531873.
A recent report has indicated that cadmium-induced testicular damage in CF-1 mice can be prevented by pretreatment with calmodulin inhibitors such as chlorpromazine (CPZ), trifluoperazine, or N-(6-aminohexyl)-5-chloro-1-naphthalene sulfonamide (W-7). However, the basis of this tolerance to cadmium is unclear and has not been demonstrated in any species other than mice. Thus, we examined the effects of the calmodulin inhibitor CPZ on cadmium toxicity in male Wistar (WF/NCr) rats. A single sc injection of 25 mumol CdCl2/kg proved nonlethal over 24 h but caused the typical spectrum of testicular lesions and increases in hemoglobin content (as assessed by hemoglobin absorbance in testicular supernatant). Pretreatment with 40 mumol CPZ/kg had no effect on cadmium-induced testicular lesions but did reduce testicular hemoglobin content, while 120 mumol CPZ/kg moderately reduced the severity of testicular lesions and hemoglobin contents. CPZ pretreatment in some cases increased cadmium content in liver and reduced testicular content but had no effect on renal levels. Cadmium treatment markedly increased hepatic and renal metallothionein (MT), a metal-binding protein often associated with tolerance to cadmium. CPZ alone likewise increased hepatic MT and MT mRNA, but did not modify renal MT, renal MT mRNA, or testicular MT mRNA. In contrast to liver and kidney, testicular cadmium-binding protein (TCBP) decreased in rats exposed only to cadmium or to CPZ, while CPZ pretreatment had no further effect on cadmium-induced reductions in TCBP levels. These results indicate that, like mice, CPZ in rats can reduce the testicular toxicity of cadmium as indicated by CPZ-induced reductions in testicular vascular lesions and hemoglobin contents. However, in rats CPZ has a less dramatic effect on such cadmium-induced lesions than in mice. The CPZ-induced stimulation of hepatic MT gene expression or modification of toxicokinetics may both play roles in this acquired tolerance to cadmium.
最近的一份报告表明,用钙调蛋白抑制剂如氯丙嗪(CPZ)、三氟拉嗪或N-(6-氨基己基)-5-氯-1-萘磺酰胺(W-7)进行预处理,可以预防CF-1小鼠中镉诱导的睾丸损伤。然而,这种对镉的耐受性的基础尚不清楚,并且除小鼠外尚未在任何其他物种中得到证实。因此,我们研究了钙调蛋白抑制剂CPZ对雄性Wistar(WF/NCr)大鼠镉毒性的影响。单次皮下注射25 μmol CdCl₂/kg在24小时内被证明无致死性,但导致了典型的睾丸损伤谱,并使血红蛋白含量增加(通过睾丸上清液中的血红蛋白吸光度评估)。用40 μmol CPZ/kg进行预处理对镉诱导的睾丸损伤没有影响,但确实降低了睾丸血红蛋白含量,而120 μmol CPZ/kg适度降低了睾丸损伤的严重程度和血红蛋白含量。在某些情况下,CPZ预处理增加了肝脏中的镉含量并降低了睾丸中的镉含量,但对肾脏中的镉含量没有影响。镉处理显著增加了肝脏和肾脏中的金属硫蛋白(MT),这是一种通常与对镉的耐受性相关的金属结合蛋白。单独使用CPZ同样增加了肝脏中的MT和MT mRNA,但没有改变肾脏中的MT、肾脏中的MT mRNA或睾丸中的MT mRNA。与肝脏和肾脏不同,仅暴露于镉或CPZ的大鼠中睾丸镉结合蛋白(TCBP)减少,而CPZ预处理对镉诱导的TCBP水平降低没有进一步影响。这些结果表明,与小鼠一样,大鼠中的CPZ可以降低镉的睾丸毒性,如CPZ诱导的睾丸血管损伤和血红蛋白含量降低所示。然而,在大鼠中,CPZ对这种镉诱导的损伤的影响不如在小鼠中显著。CPZ诱导的肝脏MT基因表达刺激或毒代动力学改变可能都在这种对镉的获得性耐受性中起作用。